A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study

Covid19 Vaccine Clinical Trial

Official title:

A Phase II, Prospective, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Extension Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05048849
• Other study ID #: CT-COV-21e
• Status: Completed
• Phase: Phase 2
• Start date: July 19, 2021
• Est. completion date: April 12, 2022

Study information

• Verified date: September 2021
• Source: Medigen Vaccine Biologics Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine who are generally healthy or with stable pre-existing health conditions and have received 2 doses of Placebo in the main study CT-COV-21

Description:

This is an extension study of the main study CT-COV-21, "A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901."

This extension study is a prospective, open-label, multicenter study. In this extension study, approximately 500 participants who received the placebo and have remained blinded in the main study until Day 119 (90 days after the second vaccination of the main study) are enrolled and receive MVC-COV1901. Each participant will receive 2 doses of MVC-COV1901, administered 28 days apart via IM injection in the deltoid region, preferably of the non-dominant arm, at Day 1 and Day 29.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 274
• Est. completion date: April 12, 2022
• Est. primary completion date: November 8, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria

1. Participants who are in the placebo arm of the main study (CT-COV-21), and are unblinded due to urgent condition other than safety events (i.e. on request from participants with high risk of acquiring and transmitting infection) after Day 119, are eligible.

2. Female participant must:

1. Be either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal;

2. Or, if of childbearing potential, be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following the last injection of study intervention. Acceptable forms include:

i. Implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system ii. Established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository c. Have a negative pregnancy test

3. Participant is willing and able to comply with all required study visits and follow-up required by this protocol.

4. Participant or the participant's legal representative must understand the procedures of the study and provide written informed consent

Exclusion Criteria

1. Pregnant or breast feeding or have plan to become pregnant in 30 days after last administration of study intervention.

2. Employees at the investigator's site, of the Sponsor or the contract research organization (CRO) directly involved in the conduct of the study.

Prior/Concomitant Therapy

3. Currently receiving or received any investigational intervention within 30 days prior to the first dose of study intervention.

4. Administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to the first dose of study intervention.

5. Administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the first dose of study intervention.

6. Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of study intervention.

7. Currently receiving or anticipate to receive treatment with tumor necrosis factor (TNF)-a inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of study intervention.

8. Major surgery or any radiation therapy within 12 weeks prior to the first dose of study intervention

9. Participant with previous known or potential exposure to SARS-CoV-1 or 2 viruses or received any other COVID-19 vaccine.

10. Participant with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901.

11. Body (oral, rectal, or ear) temperature = 38.0°C or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the first dose of study intervention.

Related Conditions & MeSH terms

• COVID-19
• Covid19 Vaccine

Intervention

Biological:
• MVC-COV1901(S protein with adjuvant)
Approximately 500 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Locations

Country	Name	City	State
Taiwan	Changhua Christian Hospital	Changhua
Taiwan	Kaohsiung Medical University Chung-Ho Memorial Hospital	Kaohsiung
Taiwan	China Medical University Hospital	Taichung
Taiwan	National Cheng Kung University Hospital	Tainan
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Taipei Medical University Hospital	Taipei
Taiwan	Taipei Municipal Wan Fang Hospital	Taipei
Taiwan	Taipei Veteran General Hospital	Taipei
Taiwan	Tri-Service General Hospital	Taipei
Taiwan	Chang-Guang Memorial Hospital Lin-Kou	Taoyuan
Taiwan	Tao-Yuan General Hospital	Taoyuan

Sponsors (1)

Lead Sponsor	Collaborator
Medigen Vaccine Biologics Corp.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of confirmed COVID-19 cases (Efficacy of MVC-COV1901)	To estimate the efficacy of MVC-COV1901, as compared to placebo, in the prevention of COVID-19 in terms of : The number of laboratory-confirmed COVID-19 cases occurring = 15 days after any dose of study intervention.; The number of laboratory-confirmed COVID-19 severe cases occurring = 15 days after any dose of study intervention.	Day 1 to 180 days after second vaccination
Primary	Number of Adverse Event (Safety of MVC-COV1901)	To evaluate the safety and tolerability of MVC-COV1901 from Day 1 to 28 days after the second dose of study intervention in terms of the number of participants with the occurrence of: Solicited local AEs (up to 7 days after each dose of study intervention); Solicited systemic AEs (up to 7 days after each dose of study intervention); Unsolicited AEs (up to 28 days after each dose of study intervention); AE of Special Interest (AESI); Vaccine-Associated Enhanced Disease(VAED); Serious adverse events (SAEs)	Day 1 to 28 days after second vaccination
Primary	Percentage of Adverse Event (Safety of MVC-COV1901)	To evaluate the safety and tolerability of MVC-COV1901 from Day 1 to 28 days after the second dose of study intervention in terms of the percentage of participants with the occurrence of: Solicited local AEs (up to 7 days after each dose of study intervention); Solicited systemic AEs (up to 7 days after each dose of study intervention); Unsolicited AEs (up to 28 days after each dose of study intervention); AE of Special Interest (AESI); Vaccine-Associated Enhanced Disease(VAED); Serious adverse events (SAEs)	Day 1 to 28 days after second vaccination
Primary	Immunogenicity of MVC-COV1901(Neutralizing Antibody)	To evaluate the immunogenicity of MVC-COV1901 in terms of neutralizing antibody titers 28 days after the second dose of study intervention	Day 1 to 28 days after second vaccination
Secondary	Number of Adverse Event over the study period (Secondary Safety of MVC-COV1901)	To evaluate the safety of MVC-COV1901 over the study period in terms of the number of participants with the occurrence of: >= Grade 3 AE; AE of Special Interest (AESI); Vaccine-Associated Enhanced Disease(VAED); Serious adverse events (SAEs)	Day 1 to 180 days after second vaccination
Secondary	Percentage of Adverse Event over the study period (Secondary Safety of MVC-COV1901)	To evaluate the safety of MVC-COV1901 over the study period in terms of the percentage of participants with the occurrence of: >= Grade 3 AE; AE of Special Interest (AESI); Vaccine-Associated Enhanced Disease(VAED); Serious adverse events (SAEs)	Day 1 to 180 days after second vaccination
Secondary	Immunogenicity of MVC-COV1901(Antigen-specific Immunoglobulin)	To evaluate the immunogenicity of MVC-COV1901 in terms of antigen-specific immunoglobulin 28 days after the second dose of study intervention	Day 1 to 28 days after second vaccination